PubRank

Stefano Vella

Author PubWeight™ 115.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006 7.49
2 Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002 5.56
3 Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 4.57
4 Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005 4.40
5 Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004 3.74
6 Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004 3.06
7 Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003 2.81
8 Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 2004 2.53
9 Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. AIDS 2005 2.48
10 Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002 2.44
11 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
12 Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007 1.89
13 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med 2006 1.65
14 Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012 1.57
15 Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005 1.55
16 A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003 1.51
17 Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology 2015 1.43
18 The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 2011 1.41
19 Gender differences in the treatment of HIV infection. Pharmacol Res 2008 1.39
20 Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 2007 1.39
21 Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr 2007 1.38
22 Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003 1.37
23 Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003 1.36
24 Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol 2005 1.32
25 Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. J Clin Virol 2009 1.28
26 HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res 2011 1.28
27 Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 2013 1.23
28 Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol 2009 1.13
29 Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. AIDS 2008 1.10
30 Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004 1.09
31 Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005 1.04
32 Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003 1.04
33 Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS One 2013 1.02
34 A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 2011 1.01
35 Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 2007 0.99
36 Redox features of the cell: a gender perspective. Antioxid Redox Signal 2007 0.97
37 HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006 0.96
38 Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol 2003 0.96
39 Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004 0.96
40 Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol 2012 0.95
41 Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds. Antimicrob Agents Chemother 2006 0.94
42 Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012 0.93
43 Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002 0.93
44 Inequalities in health: access to treatment for HIV/AIDS. Ann Ist Super Sanita 2007 0.92
45 Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol 2011 0.91
46 Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda. AIDS Res Hum Retroviruses 2007 0.90
47 Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003 0.90
48 Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003 0.90
49 Optimization and simplification of antiretroviral therapy for adults and children. Curr Opin HIV AIDS 2013 0.89
50 Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS 2002 0.89
51 Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. J Med Virol 2012 0.87
52 The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One 2010 0.87
53 The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. J Infect Dis 2013 0.85
54 Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med 2013 0.84
55 Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique. AIDS Res Hum Retroviruses 2009 0.84
56 Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial. AIDS Res Hum Retroviruses 2010 0.83
57 Glances in Immunology of HIV and HCV Infection. Adv Virol 2012 0.82
58 Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunol Lett 2005 0.82
59 Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. J Med Virol 2007 0.81
60 Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. AIDS 2007 0.81
61 High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol 2003 0.81
62 Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 2005 0.81
63 Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells. BMC Pharmacol Toxicol 2013 0.80
64 Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV. J Acquir Immune Defic Syndr 2006 0.80
65 Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. J Antimicrob Chemother 2004 0.80
66 Antiretroviral drug resistance and HIV/AIDS in the developing world. J HIV Ther 2002 0.80
67 Italian attention-deficit/hyperactivity disorder registry. Pediatrics 2004 0.80
68 A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Ther Deliv 2011 0.80
69 CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis. Ann N Y Acad Sci 2003 0.79
70 Non-B HIV type 1 subtypes: replicative capacity and response to antiretroviral therapy. AIDS Res Hum Retroviruses 2004 0.79
71 The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine 2011 0.79
72 Commentary: Antiretroviral therapy initiation criteria in low resource settings--from 'when to start' to 'when not to start'. AIDS 2014 0.79
73 Dynamic NAD(P)H post-synaptic autofluorescence signals for the assessment of mitochondrial function in a neurodegenerative disease: monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model. Mitochondrion 2009 0.79
74 Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV. J Acquir Immune Defic Syndr 2011 0.78
75 Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique. J Acquir Immune Defic Syndr 2008 0.78
76 Recovery of interleukin-17 production from interleukin-15-stimulated CD4+ mononuclear cells in HIV-1-infected patients with sustained viral suppression. J Interferon Cytokine Res 2013 0.78
77 Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. HIV Clin Trials 2007 0.78
78 Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. J Virol Methods 2010 0.78
79 Enhanced brain performance in mice following postnatal stress. J Endocrinol 2012 0.77
80 [DREAM project early results (drug resources enhancement against AIDS in Mozambique)]. Ig Sanita Pubbl 2003 0.77
81 The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. AIDS 2002 0.77
82 Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substances. Peptides 2010 0.77
83 In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr 2002 0.77
84 Weight changes during and after 6 months of breastfeeding in HIV-infected mothers receiving antiretroviral therapy in Malawi. AIDS Res Hum Retroviruses 2014 0.77
85 The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. BMC Infect Dis 2014 0.76
86 Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy. Ann N Y Acad Sci 2006 0.75
87 Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. J Child Adolesc Psychopharmacol 2013 0.75
88 Absence of unfavorable effect of atomoxetine on growth in pediatric patients is still not demonstrated. Pediatrics 2006 0.75
89 Viral sequence analysis of HIV-positive women and their infected children: insight on the timing of infection and on the transmission network. AIDS Res Hum Retroviruses 2014 0.75
90 Post-natal stress-induced endocrine and metabolic alterations in mice at adulthood involve different pro-opiomelanocortin-derived peptides. Peptides 2010 0.75
91 Unite forces to validate biomarkers in the quest for lasting HIV remission. AIDS 2016 0.75
92 Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. J Med Microbiol 2009 0.75
93 Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. J Antimicrob Chemother 2013 0.75
94 Virus Variability and Its Impact on HIV and Hepatitis Therapy. Adv Virol 2012 0.75
95 HIV clinical research in developing countries: challenges and priorities. J HIV Ther 2004 0.75
96 Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. AIDS 2016 0.75
97 Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008 0.75
98 Access to HIV care and treatment in the developing world: responding to the objections. AIDS Clin Care 2002 0.75
99 Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. J Acquir Immune Defic Syndr 2016 0.75
100 Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART? J HIV Ther 2003 0.75